Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ivermectin for preventing and treating COVID-19
Maria Popp, Stefanie Reis, Selina Schießer, et al.
Cochrane library (2022) Vol. 2024, Iss. 3
Open Access | Times Cited: 156

Showing 1-25 of 156 citing articles:

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
Carolyn T. Bramante, Jared D. Huling, Christopher J. Tignanelli, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 7, pp. 599-610
Open Access | Times Cited: 206
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Steven Lim, Chee Peng Hor, Kim Heng Tay, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 4, pp. 426-426
Open Access | Times Cited: 90
Artificial Intelligence in Biological Sciences
Abhaya Bhardwaj, Shristi Kishore, Dhananjay K. Pandey
Life (2022) Vol. 12, Iss. 9, pp. 1430-1430
Open Access | Times Cited: 78
Medicine is plagued by untrustworthy clinical trials. How many studies are faked or flawed?
Richard Van Noorden
Nature (2023) Vol. 619, Iss. 7970, pp. 454-458
Closed Access | Times Cited: 45
The regrettable story of the “Covid Kit” and the “Early Treatment of Covid-19” in Brazil
Leonardo Furlan, Bruno Caramelli
The Lancet Regional Health - Americas (2021) Vol. 4, pp. 100089-100089
Open Access | Times Cited: 79
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2022) Vol. 2022, Iss. 9
Open Access | Times Cited: 59
Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis
Stephanie Weibel, Maria Popp, Stefanie Reis, et al.
Research Synthesis Methods (2022) Vol. 14, Iss. 3, pp. 357-369
Open Access | Times Cited: 54
COVID‐19 in Latin America and the Caribbean: Two years of the pandemic
Alvaro Schwalb, Eleonora Armyra, Melissa Méndez‐Aranda, et al.
Journal of Internal Medicine (2022) Vol. 292, Iss. 3, pp. 409-427
Open Access | Times Cited: 52
Data capture and sharing in the COVID-19 pandemic: a cause for concern
Louis Dron, Vinusha Kalatharan, Alind Gupta, et al.
The Lancet Digital Health (2022) Vol. 4, Iss. 10, pp. e748-e756
Open Access | Times Cited: 51
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial
Dora Buonfrate, Fabio Chesini, Davide Martini, et al.
International Journal of Antimicrobial Agents (2022) Vol. 59, Iss. 2, pp. 106516-106516
Open Access | Times Cited: 48
Efficacy of repurposed antiviral drugs: Lessons from COVID-19
Miguel Ángel Martı́nez
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1954-1960
Open Access | Times Cited: 40
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria‐Inti Metzendorf, Rebecca Kuehn, et al.
Cochrane library (2023) Vol. 2023, Iss. 11
Open Access | Times Cited: 23
Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Gail Hayward, Ly‐Mee Yu, Paul Little, et al.
Journal of Infection (2024) Vol. 88, Iss. 4, pp. 106130-106130
Open Access | Times Cited: 12
The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis
Shivani Singh, Simon Boyd, William HK Schilling, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 5, pp. 935-945
Open Access | Times Cited: 10
Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective
J. Carlos Menéndez
Molecules (2022) Vol. 27, Iss. 3, pp. 658-658
Open Access | Times Cited: 32
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 30
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Zhilong Song, Senyuan Shi, Yongli Zhang
Heliyon (2024) Vol. 10, Iss. 6, pp. e27647-e27647
Open Access | Times Cited: 7
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials
Nathália Mariana Santos Sansone, Matheus Negri Boschiero, Fernando Augusto Lima Marson
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2206-2206
Open Access | Times Cited: 7
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Arielle Elkrief, Julie Wu, Chinmay Jani, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 303-330
Open Access | Times Cited: 34
Treatments for COVID-19: Lessons from 2020 and new therapeutic options
Fanny Salasc, Thomas Lahlali, Emilie Laurent, et al.
Current Opinion in Pharmacology (2021) Vol. 62, pp. 43-59
Open Access | Times Cited: 33
Completeness and Spin of medRxiv Preprint and Associated Published Abstracts of COVID-19 Randomized Clinical Trials
Hannah Spungen, Jason Burton, Stephen Schenkel, et al.
JAMA (2023) Vol. 329, Iss. 15, pp. 1310-1310
Open Access | Times Cited: 14
Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?
Wolfgang Löscher
Epilepsia (2023) Vol. 64, Iss. 3, pp. 553-566
Open Access | Times Cited: 13
Green and Smart Quantitative Quality Control for Veterinary Mixture of Ivermectin and Clorsulon: Ecological Evaluation of Spectral Analyses via Analytical Eco-Scale, Green Analytical Procedure Index, and Analytical GREEnness Metric Approaches
Miranda F. Kamal, Rasha M. Youssef, Samir Morshedy, et al.
Journal of AOAC International (2023) Vol. 106, Iss. 6, pp. 1455-1463
Closed Access | Times Cited: 13
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Md. Easin Mia, Mithu Howlader, Farzana Akter, et al.
Clinical Pathology (2024) Vol. 17
Open Access | Times Cited: 5
A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
Yasser Mohamed, Yousra A. El‐Maradny, Ahmed K. Saleh, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113499-113499
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top